Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.

Jiang J, Lin C, Liu N, Zhang Z, Sun Y, Fang X, Qi J.

APMIS. 2013 Oct;121(10):997-1003. doi: 10.1111/apm.12135. Epub 2013 Jul 24.

PMID:
23879478
2.

Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.

Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A.

J Neurooncol. 2008 Aug;89(1):73-87. doi: 10.1007/s11060-008-9588-3. Epub 2008 Apr 17.

PMID:
18418552
3.

Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.

Skiriute D, Tamasauskas S, Asmoniene V, Saferis V, Skauminas K, Deltuva V, Tamasauskas A.

J Neurooncol. 2011 Mar;102(1):89-94. doi: 10.1007/s11060-010-0291-9. Epub 2010 Jul 4.

PMID:
20607352
4.

Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.

Ke HL, Ke RH, Li B, Wang XH, Wang YN, Wang XQ.

Acta Neurochir (Wien). 2013 Jan;155(1):165-71. doi: 10.1007/s00701-012-1512-0. Epub 2012 Oct 5.

PMID:
23053286
5.

Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.

Serna E, Morales JM, Mata M, Gonzalez-Darder J, San Miguel T, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Monleon D.

PLoS One. 2013 Jun 28;8(6):e67291. doi: 10.1371/journal.pone.0067291. Print 2013.

6.

Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.

Lee SH, Lee YS, Hong YG, Kang CS.

APMIS. 2014 Jan;122(1):16-24. doi: 10.1111/apm.12079. Epub 2013 Jun 12.

PMID:
23756256
7.

Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.

Trinkaus M, Vranic A, Dolenc VV, Lah TT.

Int J Biol Markers. 2005 Jan-Mar;20(1):50-9.

PMID:
15832773
8.

Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.

Ke HL, Ke RH, Li ST, Li B, Lu HT, Wang XQ.

J Neurooncol. 2013 Jun;113(2):327-32. doi: 10.1007/s11060-013-1121-7. Epub 2013 Mar 25.

PMID:
23525949
9.

Molecular biological determinations of meningioma progression and recurrence.

Linsler S, Kraemer D, Driess C, Oertel J, Kammers K, Rahnenführer J, Ketter R, Urbschat S.

PLoS One. 2014 Apr 10;9(4):e94987. doi: 10.1371/journal.pone.0094987. eCollection 2014.

10.

Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.

Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fèvre-Montange M.

Clin Neuropathol. 2008 Sep-Oct;27(5):334-45.

11.

Fatty acid synthase is a predictive marker for aggressiveness in meningiomas.

Makino K, Nakamura H, Hide T, Yano S, Kuroda J, Iyama K, Kuratsu J.

J Neurooncol. 2012 Sep;109(2):399-404. doi: 10.1007/s11060-012-0907-3. Epub 2012 Jun 29.

PMID:
22744755
12.

Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.

Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A.

APMIS. 2009 Sep;117(9):651-9. doi: 10.1111/j.1600-0463.2009.02516.x.

PMID:
19703125
13.
14.

Does protein expression predict recurrence of benign World Health Organization grade I meningioma?

Kärjä V, Sandell PJ, Kauppinen T, Alafuzoff I.

Hum Pathol. 2010 Feb;41(2):199-207. doi: 10.1016/j.humpath.2009.06.020. Epub 2009 Oct 3.

PMID:
19801161
15.

P53 overexpression and proliferative potential in malignant meningiomas.

Nagashima G, Aoyagi M, Yamamoto M, Yamamoto S, Wakimoto H, Ohno K, Yamamoto K, Hirakawa K.

Acta Neurochir (Wien). 1999;141(1):53-61; discussion 60-1.

PMID:
10071687
16.

Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue.

Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC.

J Neurooncol. 2008 Mar;87(1):43-50. Epub 2007 Nov 30.

PMID:
18060363
17.

Fatty acid synthase as a novel target for meningioma therapy.

Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C.

Neuro Oncol. 2010 Aug;12(8):844-54. doi: 10.1093/neuonc/noq004. Epub 2010 Feb 5.

18.

Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY.

J Neurooncol. 2010 Nov;100(2):217-23. doi: 10.1007/s11060-010-0164-2. Epub 2010 Apr 29.

PMID:
20428925
19.

Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.

Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J.

Histol Histopathol. 2010 Mar;25(3):341-9. doi: 10.14670/HH-25.341.

PMID:
20054806
20.

S100A5: a marker of recurrence in WHO grade I meningiomas.

Hancq S, Salmon I, Brotchi J, De Witte O, Gabius HJ, Heizmann CW, Kiss R, Decaestecker C.

Neuropathol Appl Neurobiol. 2004 Apr;30(2):178-87.

PMID:
15043715

Supplemental Content

Support Center